Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%)
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution